Please login to the form below
small cell lung cancer
This page shows the latest small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.
New dosing option for AZ’s Imfinzi approved in the EU and UK
new dosing option in locally advanced, unresectable non-small cell lung cancer (NSCLC). ... The new dosing regimen is consistent with Imfinzi’s approved dosing in extensive-stage small cell lung cancer (ES-SCLC).
Latest news
-
Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation
The BTD covers the combination treatment in the first-line setting for people with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR ... The TIGIT-targeting treatment is being investigated in a number of
-
Amgen aims for first KRAS inhibitor approval in the US
metastatic non-small cell lung cancer (NSCLC), who have received at least one prior systemic therapy. ... Amgen is due to submit the detailed results from the phase 2 study to the International Association for the Study of Lung Cancer World Conference on
-
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in
-
Merck strengthens oncology pipeline with $2.75bn VelosBio deal
Merck &Co (MSD) has agreed to acquire VelosBio for $2.75bn, giving MSD access to a number of potential cancer treatments in the process. ... breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small
-
Keytruda growth helps Merck to offset COVID-19 impact in Q3
In the third quarter, sales of Keytruda grew by 24% to $2.2bn reflecting growing momentum in a number of non-small cell lung cancer indications, as well as uptake in ... other areas including adjuvant melanoma and bladder cancer.
More from news
Approximately 9 fully matching, plus 649 partially matching documents found.
Latest Intelligence
-
Successful product commercialisation: what can we learn from the rare disease setting?
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical ... For novel therapies (including medicines aimed at rare
-
Unlocking the potential of precision medicine in oncology
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
Amgen brought the first approved BiTE molecule targeting CD19 to patients and we continue to pioneer the bispecific space by exploring this technology across solid tumors, such as small-cell lung ... the other is designed to engage with any
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute. ... The NF1 gene provides instructions to make neurofibromin which acts as a tumour suppressant but if it mutates, tumour cell growth
-
Staying ahead in the era of precision medicine
For example, Lung-MAP, a large-scale umbrella trial in non-small cell lung cancer, was one of the first to involve partnerships between several groups including the FDA, NCI, advocacy ... The challenges around precision medicine are illustrated perfectly
More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Merck appoints ex-Pfizer exec as global head of oncology
In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
-
Charles Morris appointed chief development officer at ImmunoGen
Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech. ... Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung
-
Axelar appoints Carl Harald Janson as CEO
Takes control as company prepares to take novel cancer drug to proof-of-concept. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Delphi Technique Virtual Co-creation: A Customer Story
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Lenalidomide. Revlimid. Celgene. Thalidomide. Thalomid. Celgene. Melphalan. Multiple brands. -. Erlotinib. Tarceva. Genentech. Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer. ... Non-small cell lung cancer treatments,
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
-
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),
-
How pembrolizumab will change the management of advanced lung cancer
The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- PHE study finds people who have had COVID-19 can still transmit the virus
- New study identifies drugs that are safe to use in COVID-19 treatment
- J&J trims the size of its phase 3 COVID-19 vaccine trial
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Experimental Chinese COVID-19 vaccine is safe, according to researchers
- Live Webinar: COVID-19 Has Changed Live Events Forever!
- New hire and promotions announced at Evoke KYNE
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Lucid Group bolster its talent with a further twelve new starters for 2021
- UK pharmacies to begin administering COVID-19 vaccinations
- PHE study finds people who have had COVID-19 can still transmit the virus
PMHub
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...
Latest intelligence
- AstraZeneca’s focus on diagnosing and managing chronic kidney disease
- People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
- Delphi Technique Virtual Co-creation: A Customer Story
- How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
- Three ways AI will change healthcare in the next decade
- Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...
Quick links
Infographics
